BATMMAAN begins: These may be the dominant stocks for next year.
A new acronym has been making the rounds since another potential tech kingmaker — Broadcom — began closing in on the $1 trillion market cap club last week.
A new acronym has been making the rounds since another potential tech kingmaker — Broadcom — began closing in on the $1 trillion market cap club last week.
For all the extreme bullishness about 2025, Wall Street is just a bit edgy as the Federal Reserve looks set to deliver its final interest rate of 2024 and give a glimpse into next year. Remarkably, the Dow Jones Industrial Average's 9-day losing streak is the longest negative run since 1978 - but the index is still just under 4% from record highs set earlier this month. As Treasury yields have backed up sharply again over the past fortnight - even as the latest U.S. industrial production and retail sales excluding autos missed forecasts for last month - the yearend is looking more anxious than ebullient new year forecasts suggest.
Jefferies initiated a "buy" rating on Rocket Pharmaceuticals, based on the biotech firm's experimental gene therapies.
Zach Jecklin of Echo Global Logistics discusses the importance of providing good service through difficult freight markets, Echo’s strategy to leverage AI and how technology can help maintain relationships without eliminating human oversight. The post Focus on relationships is the key to navigating market downturns appeared first on FreightWaves.
December is shaping up to be a tale of two markets.
An investment firm's analysts compile a list of their top tech recommendations for the coming year.
US benchmark equity indexes were higher ahead of the Federal Reserve's latest monetary policy decisi
In 2020, Lego launched its adult-focused category. Adults also introduce kids to Lego, making them a group critical to the Danish toymaker.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial will enroll 64 patients with moderate to severe atopic dermatitis who previously failed one prior topical or systemic therapy. These doses were selected based on the company’s prior experience evaluating soquelitinib in T-cell lymphoma patients. The company is reporting complete results from Cohort 1 of the trial, which inc
Tender rejection rate rises as holidays approach The tender rejection rate has risen steadily since early October despite tender volume declining. That implies that capacity is leaving the market, which […] The post Freight market shows additional signs of recovery appeared first on FreightWaves.